Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $8.37B.
ENTERPRISE VALUE (EV)
$8.37B
Kymera Therapeutics, Inc.
Market Cap
$8.72B
Enterprise Value (EV)
$8.37B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.72B | $8.37B |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | $9.48B |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | $8.51B |
| Bruker Corporation (BRKRP)vs › | $8.93B | $10.66B |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | $8.87B |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | $4.74B |
| Bruker Corporation (BRKR)vs › | $9.21B | $10.94B |
| Insulet Corp. (PODD)vs › | $9.33B | $9.75B |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | $8.26B |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | $7.34B |
Market Cap
$8.72B
Total Debt
$13.76M
Cash
$357.01M
Enterprise Value
$8.37B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
